Solara Active Pharma Schedules Q2FY27 Earnings Conference Call for 16th Oct'26
Solara Active Pharma Sciences Ltd 路 Intimation 路 16 Oct 2026, 4:00 pm
Solara Active Pharma Schedules Q2FY27 Earnings Conference Call for 16th Oct'26 Solara Active Pharma Sciences Limited has scheduled an analyst and investor conference call on Friday, 16th Oct'26, at 4:00 PM IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2FY27). The call will feature participation from senior leadership, including MD & CEO Sandeep Rao and CFO Sarat Kumar. Interested market participants can join via universal access numbers (+91 22 6280 1346 / +91 22 7115 8247) or pre-register via Diamond Pass.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 路 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... 路 18 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 路 17 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 路 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA .... 路 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. 路 16 Oct 2026
